SCHEMBL14003975

SCHEMBL14003975

CC(=O)CCC(=O)Oc1ccc(/C=C/c2cc(C)cc(O)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.48
▸ LMNA P02545 5/20 0.48
▸ MAPT P10636 5/20 0.48
▸ KDM4E B2RXH2 4/20 0.48
▸ MEN1 O00255 4/20 0.48
▸ TTR P02766 3/20 0.48
▸ TP53 P04637 3/20 0.48
▸ CYP3A4 P08684 3/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ PTGS2 P35354 4/20 0.44
▸ CYP1A1 P04798 3/20 0.44
▸ CYP1B1 Q16678 3/20 0.44
▸ PTGS1 P23219 2/20 0.44
▸ ALOX12 P18054 1/20 0.44
▸ ALB P02768 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ HTT P42858 2/20 0.43
▸ TUBB4A P04350 2/20 0.42
▸ TUBB P07437 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12061383 0.92 LMNA (0.53) KMT2ALMNAMAPTKDM4EMEN1
SCHEMBL13869475 0.90 KMT2A (0.58) KMT2ALMNAMAPTKDM4EMEN1
SCHEMBL17243734 0.88 BCL9 (0.46) KMT2ALMNAMAPTKDM4EMEN1
SCHEMBL13239069 0.86 HDAC8 (0.43) KMT2ALMNAMAPTKDM4EMEN1
SCHEMBL13345755 0.85 KMT2A (0.44) KMT2ALMNAMAPTKDM4EMEN1
SCHEMBL18380782 0.84 PTGS2 (0.55) KMT2ALMNAMAPTKDM4EMEN1
SCHEMBL18471992 0.83 LMNA (0.69) KMT2ALMNAMAPTKDM4EMEN1
SCHEMBL3687875 0.81 KMT2A (0.75) KMT2ALMNAMAPTKDM4EMEN1
SCHEMBL3683227 0.81 KMT2A (0.75) KMT2ALMNAMAPTKDM4EMEN1
SCHEMBL18380781 0.79 ALB (0.62) KMT2ALMNAMAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293679-A1 Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors CARDAX PHARMACEUTICALS, INC. 2008-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293679-A1 Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors LPL, ALOX12, LCLAT1 KMT2A 2820/4885LMNA 92/4885MAPT 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback